Dave joined Horizon Pharma in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He has more than 30 years of experience in the healthcare industry, with the last 15 years dedicated to developing and commercializing treatments for rare diseases. Prior to joining us, Dave was chief commercial officer at Raptor, where he led the global commercialization of PROCYSBI® and QUINSAIR®. Prior to Raptor, he held chief commercial and corporate development roles at Allergen Research Corporation, a developer of treatments for food allergies, Dynavax Technologies, a drug development and vaccine company and Aerovance, Inc., a biotechnology company. Dave also held senior-level leadership positions at Dr. Reddy’s Laboratories, Inc., Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for cystic fibrosis and ACTIMMUNE® for the treatment of multiple rare diseases. Dave joined Horizon Pharma in October 2016 as part of the Raptor Pharmaceutical Corp. acquisition. He has more than 30 years of experience in the healthcare industry, with the last 15 years dedicated to developing and commercializing treatments for rare diseases. Prior to joining us, Dave was chief commercial officer at Raptor, where he led the global commercialization of PROCYSBI® and QUINSAIR®. Prior to Raptor, he held chief commercial and corporate development roles at Allergen Research Corporation, a developer of treatments for food allergies, Dynavax Technologies, a drug development and vaccine company and Aerovance, Inc., a biotechnology company. Dave also held senior-level leadership positions at Dr. Reddy’s Laboratories, Inc., Chiron Corporation, InterMune, Inc. and Parke-Davis/Pfizer, where he led the development and commercialization of several market-leading products, including TOBI® for cystic fibrosis and ACTIMMUNE® for the treatment of multiple rare diseases.

General Science